Biopharmas raising money in public or private financings, including: American Cancer Society, Cellcentric, Concentric Analgesics, Kyverna, Sierra Oncology, Veneno Technologies.
Mabwell Bioscience Co. Ltd. raised ¥3.48 billion ($547.9 million) in a Shanghai STAR Market IPO on Jan. 18 to support company R&D efforts and plans to build an antibody production plant. Though oversubscribed, the offering got a cool market reception, with shares plunging nearly 30% from a ¥32 open (US$27.96), then closing at ¥24.50 on the first day of trading before recovering slightly to ¥27.40 on Jan. 20.
LONDON – Cytovation AS has raised $20 million in a series A, enabling it to expand the monotherapy arm of a phase I/II trial of its tumor membrane immunotherapy, Cypep-1, and to test it in three combination arms with the checkpoint inhibitor Keytruda (pembrolizumab).
Leyden Laboratories BV has raised $140 million in a series B financing round to develop drugs that treat whole families of viruses, including a wide-spectrum flu antibody licensed from Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit earlier this month.
TORONTO – Hyivy Health Inc. has secured CA$1.1 million (US$888,000) in pre-seed funding to manufacture, test and obtain medical device approval for a women’s pelvic rehabilitation platform and to explore its use for relieving pelvic pain during clinical trials this summer.
RSS
